Tech Company Financing Transactions

FLX Bio Funding Round

On 4/30/2016, FLX Bio landed $50 million in Series B funding from Celgene, Kleiner Perkins Caufield & Byers and The Column Group.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The funds will be used to support further discovery and development of its pipeline of novel immuno-oncology compounds and to advance development of the company's Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia.

Company Information

Company Status
Private & Independent
Mailing Address
561 Eccles Ave.
South San Francisco, CA 94080
Email Address
Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents.
FLX Bio LinkedIn Company Profile
Social Media
FLX Bio Company Twitter Account
Company News
FLX Bio News
FLX Bio on Facebook
FLX Bio on YouTube

Management Team

Email & Social
Chief Executive Officer
Brian Wong
  Brian Wong LinkedIn Profile  Brian Wong Twitter Account  Brian Wong News  Brian Wong on Facebook
Chief Medical Officer
William Ho
  William Ho LinkedIn Profile  William Ho Twitter Account  William Ho News  William Ho on Facebook
Chief Operating Officer
Rekha Hemrajani
  Rekha Hemrajani LinkedIn Profile  Rekha Hemrajani Twitter Account  Rekha Hemrajani News  Rekha Hemrajani on Facebook
Vice President
Dirk Brockstedt
  Dirk Brockstedt LinkedIn Profile  Dirk Brockstedt Twitter Account  Dirk Brockstedt News  Dirk Brockstedt on Facebook
Vice President
Paul Kassner
  Paul Kassner LinkedIn Profile  Paul Kassner Twitter Account  Paul Kassner News  Paul Kassner on Facebook
Vice President
David Wustrow
  David Wustrow LinkedIn Profile  David Wustrow Twitter Account  David Wustrow News  David Wustrow on Facebook



Browse more venture capital transactions:

Prev: 4/30/2016: Sienna Biopharmaceuticals venture capital transaction
Next: 4/30/2016: Sirnaomics venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary